{"id":453344,"date":"2021-03-09T06:33:12","date_gmt":"2021-03-09T11:33:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453344"},"modified":"2021-03-09T06:33:12","modified_gmt":"2021-03-09T11:33:12","slug":"teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/","title":{"rendered":"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WAYNE, Pa., March  09, 2021  (GLOBE NEWSWIRE) &#8212; Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift<sup>\u00ae<\/sup> System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH).<\/p>\n<p>In the United States alone, more than 42 million men are affected by BPH and approximately 12 million men are under a doctor\u2019s care for the condition.<sup>1<\/sup> This common, non-cancerous enlargement of the prostate occurs as men age and can interrupt sleep, cause urinary problems, and decrease quality of life.<sup>2<\/sup><\/p>\n<p>\u201cThe UroLift System is a standard of care in my practice, and I confidently recommend it to\u00a0appropriate\u00a0patients who\u00a0face the challenge of an enlarging prostate,\u201d said\u00a0Wayne Kuang, M.D.<sup>a<\/sup> \u201cMany men are looking for alternatives to medications and major surgeries that have unwanted side effects and risks.\u00a0The UroLift System\u00a0may enable\u00a0men\u00a0to experience rapid symptom relief, recover from the procedure quickly, and return to their normal routines with minimal downtime.<sup>3,4<\/sup> This minimally invasive procedure\u00a0can\u00a0achieve\u00a0consistent results in a broad range of BPH patients with various anatomies\u00a0and a wide range of sizes.\u201d\u00a0<\/p>\n<p>\u201cCelebrating 250,000 patients treated with the UroLift System is an exciting milestone. We thank the physicians in our community who recommend the UroLift System to their patients,\u201d said Tyler Binney, President of the Teleflex Interventional Urology business unit. \u201cRecent clinical data show the UroLift System provides a superior patient experience with better sexual function, lower catheterization rates, less interference with daily activities, and higher patient satisfaction in the early recovery period.<sup>b,5<\/sup> Patients treated with the UroLift System may also achieve better outcomes in sexual function and satisfaction than men who receive medical therapy.<sup>c,8<\/sup> These positive UroLift System outcomes align with our goal at Teleflex to improve the health and quality of patients\u2019 lives.\u201d<\/p>\n<p>\n        <strong>About the UroLift<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> System<\/strong><br \/>\n        <br \/>The UroLift<sup>\u00ae<\/sup> System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction or removing prostate tissue. The UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.<sup>d,<\/sup><sup>3,6,7<\/sup> Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.<sup>3<\/sup> Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 250,000 men have been treated with the UroLift System in select markets worldwide.<sup>e<\/sup> Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2-TBK46kJBhFvc1nZugy8TgzF-K0CladHarSpupUfmsY9A_Xej20FgRzeBhzAqv3ryA6K8-EldmBFvfpEYMCeA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.UroLift.com<\/a>.<\/p>\n<p>\n        <strong>About Teleflex Interventional Urology<\/strong><br \/>\n        <br \/>The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive, and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift<sup>\u00ae<\/sup> System, a minimally invasive, permanent implant system that treats symptoms while preserving sexual function.<sup>d,<\/sup><sup>3,6,7<\/sup> Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ttijRhzdYNYRENAncLKSeMEyXTWjz3qa_pM8h-_H6RGMz-aXfhP19Gz6PhAYC_hQ2NYuPd0ZZDSqUYreui-v3A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.NeoTract.com<\/a>.<\/p>\n<p>\n        <strong>About Teleflex Incorporated<\/strong><br \/>\n        <br \/>Teleflex is a global provider of medical technologies designed to improve the health and quality of people\u2019s lives. We apply purpose-driven innovation\u2014a relentless pursuit of identifying unmet clinical needs\u2014to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4QoNY8vb6jWyk-PtmYdCrMWgALZGlfzWCZXxD2iTXMxaaxiSlcsiCijf0_nUDiUKL1MAhEw5dWk3Jn5syU7uBg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.Teleflex.com<\/a>.<\/p>\n<p>Teleflex is the home of Arrow<sup>\u00ae<\/sup>, Deknatel<sup>\u00ae<\/sup>, Hudson RCI<sup>\u00ae<\/sup>, LMA<sup>\u00ae<\/sup>, Pilling<sup>\u00ae<\/sup>, Rusch<sup>\u00ae<\/sup>, UroLift<sup>\u00ae<\/sup> and Weck<sup>\u00ae<\/sup>\u2014trusted brands united by a common sense of purpose.<\/p>\n<p>Contacts:<\/p>\n<p>For Teleflex Incorporated:<br \/>Jake Elguicze, 610.948.2836<br \/>Treasurer and Vice President, Investor Relations<\/p>\n<p>Media:<br \/>Nicole Osmer, 650.454.0504<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ltVzO7p_uwrG9TUnDtsuijvjfqZkmYpyuqySxOIv5Smxwkojb1vxJwckW8K-08R5UTdm_HPYlBbzqPxqv-9m7pxN8EGU4xL-Q0OCFmzsPfu4QN9EtwbUyVMBmZrwoDVm\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">nicole@healthandcommerce.com<\/a><\/p>\n<p>\n        <sup>a<\/sup> Dr. Wayne Kuang is a paid consultant of NeoTract | Teleflex Interventional Urology<br \/><sup>b<\/sup> Nonrandomized controlled study comparing the early patient experience following treatment with the UroLift System and Rezum\u2122 steam injection.<br \/><sup>c<\/sup> Non-head-to-head comparative study examining erectile and ejaculatory function and sexual satisfaction following treatment with the UroLift System or once-daily medical therapy from the MTOPS trial.<br \/><sup>d<\/sup> No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.<br \/><sup>e<\/sup> Management estimate based on product sales and average units per procedure.<\/p>\n<p>1. NeoTract US Market Model estimates for 2020 based on IQVIA\u2122 data; data on file.<br \/>2. Speakman, BJUI 2014<br \/>3. Roehrborn, J Urology 2013<br \/>4. Shore, Can J Urol 2014<br \/>5. Tutrone, Can J Urol 2020<br \/>6. AUA BPH Guidelines 2003, 2020<br \/>7. McVary, J Sex Med 2016<br \/>8. Roehrborn and Rukstalis. Eur Urol Focus 2020<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ebe22cb4-58fa-433b-9332-32ec18a6d9b0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift\u00ae System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH). In the United States alone, more than 42 million men are affected by BPH and approximately 12 million men are under a doctor\u2019s care for the condition.1 This common, non-cancerous enlargement of the prostate occurs as men age and can interrupt sleep, cause urinary problems, and decrease quality of life.2 \u201cThe UroLift System is a standard of care in my practice, and I confidently recommend it to\u00a0appropriate\u00a0patients who\u00a0face the challenge of an enlarging prostate,\u201d said\u00a0Wayne Kuang, M.D.a \u201cMany men are looking for alternatives to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453344","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift\u00ae System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH). In the United States alone, more than 42 million men are affected by BPH and approximately 12 million men are under a doctor\u2019s care for the condition.1 This common, non-cancerous enlargement of the prostate occurs as men age and can interrupt sleep, cause urinary problems, and decrease quality of life.2 \u201cThe UroLift System is a standard of care in my practice, and I confidently recommend it to\u00a0appropriate\u00a0patients who\u00a0face the challenge of an enlarging prostate,\u201d said\u00a0Wayne Kuang, M.D.a \u201cMany men are looking for alternatives to &hellip; Continue reading &quot;Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T11:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System\",\"datePublished\":\"2021-03-09T11:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/\"},\"wordCount\":807,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/\",\"name\":\"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=\",\"datePublished\":\"2021-03-09T11:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/","og_locale":"en_US","og_type":"article","og_title":"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System - Market Newsdesk","og_description":"WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift\u00ae System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH). In the United States alone, more than 42 million men are affected by BPH and approximately 12 million men are under a doctor\u2019s care for the condition.1 This common, non-cancerous enlargement of the prostate occurs as men age and can interrupt sleep, cause urinary problems, and decrease quality of life.2 \u201cThe UroLift System is a standard of care in my practice, and I confidently recommend it to\u00a0appropriate\u00a0patients who\u00a0face the challenge of an enlarging prostate,\u201d said\u00a0Wayne Kuang, M.D.a \u201cMany men are looking for alternatives to &hellip; Continue reading \"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T11:33:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System","datePublished":"2021-03-09T11:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/"},"wordCount":807,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/","name":"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=","datePublished":"2021-03-09T11:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjE3MyM0MDUzMTgxIzIwMDQ2NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/teleflex-reports-250000-patients-treated-for-enlarged-prostate-with-the-minimally-invasive-urolift-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift\u00ae System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453344"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453344\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}